Novel pyridine-containing azacrownethers for the chelation of therapeutic bismuth radioisotopes: Complexation study, radiolabeling, serum stability and biodistribution
Nowadays alpha-emitting radionuclides are the most perspective for target alpha therapy and 213Bi (T1/2 = 46 min) is one of the intensively studied for purpose. Despite the predominant decay by β-emission (98%) and only 2% by α-emission for 213Bi the presence of pure α-emitting 213Po and β-emitting 209Tl and 209Pb among its short-lived daughter radionuclides leads to its high therapeutic ef ficacy. The latter has already been demonstrated upon treatment of glioma, glioblastoma [1,2], neuroendocrine tumors [3] and prostate cancer [4].
Source: Nuclear Medicine and Biology - Category: Nuclear Medicine Authors: B.V. Egorova, E.V. Matazova, A.A. Mitrofanov, G.Yu. Aleshin, A.L. Trigub, A.D. Zubenko, O.A. Fedorova, Yu.V. Fedorov, S.N. Kalmykov Source Type: research
More News: Biology | Brain | Brain Tumor | Cancer | Cancer & Oncology | Glioma | Neurology | Nuclear Medicine | Prostate Cancer | Study